Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CBAYNASDAQ:MCRBNASDAQ:PHARNASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBAYCymaBay Therapeutics$32.48$32.44$7.26▼$32.50$3.73B0.324.11 million shs73 shsMCRBSeres Therapeutics$7.88+11.8%$11.52$6.64▼$30.60$68.81M2.89147,385 shs99,891 shsPHARPharming Group$9.81-2.2%$8.52$6.65▼$11.07$667.04M-0.086,447 shs1,355 shsVKTXViking Therapeutics$28.30+2.7%$26.19$18.92▼$81.73$3.09B0.754.09 million shs3.77 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBAYCymaBay Therapeutics0.00%0.00%0.00%0.00%0.00%MCRBSeres Therapeutics+11.77%-14.63%-33.28%-50.69%-61.37%PHARPharming Group-2.24%+6.29%+21.80%+14.54%-1.95%VKTXViking Therapeutics+2.50%-4.04%+27.36%-5.54%-61.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMCRBSeres Therapeutics3.2414 of 5 stars2.92.00.04.61.81.70.0PHARPharming Group2.4611 of 5 stars3.55.00.00.02.00.00.6VKTXViking Therapeutics4.6707 of 5 stars4.52.00.04.73.63.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBAYCymaBay Therapeutics 0.00N/AN/AN/AMCRBSeres Therapeutics 1.80Reduce$73.67834.86% UpsidePHARPharming Group 3.00Buy$30.00205.97% UpsideVKTXViking Therapeutics 3.00Buy$87.15207.96% UpsideCurrent Analyst Ratings BreakdownLatest MCRB, CBAY, PHAR, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$1.25 ➝ $6.004/29/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$104.004/28/2025VKTXViking TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$95.00 ➝ $75.004/24/2025VKTXViking TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.004/24/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/17/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/8/2025VKTXViking TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$30.003/26/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.003/20/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/20/2025PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00 ➝ $37.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBAYCymaBay Therapeutics$31.07M119.92N/AN/A$2.58 per share12.59MCRBSeres Therapeutics$126.33M0.54N/AN/A($0.35) per share-22.51PHARPharming Group$297.20M2.24$0.11 per share91.82$3.26 per share3.01VKTXViking TherapeuticsN/AN/AN/AN/A$3.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBAYCymaBay Therapeutics-$105.37M-$0.97N/AN/AN/AN/A-50.72%-31.04%N/AMCRBSeres Therapeutics-$113.72M-$4.60N/AN/AN/AN/AN/A-55.08%N/APHARPharming Group-$10.55M-$0.20N/A326.83N/A-6.09%-7.65%-3.82%7/30/2025 (Estimated)VKTXViking Therapeutics-$109.96M-$1.15N/AN/AN/AN/A-11.93%-11.57%7/23/2025 (Estimated)Latest MCRB, CBAY, PHAR, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025PHARPharming Group-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 million5/7/2025Q1 2025MCRBSeres Therapeutics-$0.67-$2.24-$1.57$3.75$10.00 millionN/A4/23/2025Q1 2025VKTXViking Therapeutics-$0.31-$0.41-$0.10-$0.41N/AN/A3/13/2025Q4 2024PHARPharming Group$0.07$0.05-$0.02$0.05$76.67 million$92.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBAYCymaBay TherapeuticsN/A10.9610.96MCRBSeres TherapeuticsN/A1.121.12PHARPharming Group0.413.532.76VKTXViking TherapeuticsN/A36.4736.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBAYCymaBay Therapeutics95.03%MCRBSeres Therapeutics59.34%PHARPharming Group0.03%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipCBAYCymaBay Therapeutics7.00%MCRBSeres Therapeutics4.70%PHARPharming Group2.07%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBAYCymaBay Therapeutics101114.72 million106.69 millionOptionableMCRBSeres Therapeutics3308.73 million162.03 millionOptionablePHARPharming Group28068.03 million66.62 millionNot OptionableVKTXViking Therapeutics20112.31 million106.20 millionOptionableMCRB, CBAY, PHAR, and VKTX HeadlinesRecent News About These CompaniesViking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Buy" by AnalystsMay 13 at 2:25 AM | marketbeat.comGranahan Investment Management LLC Has $12.30 Million Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 12 at 6:35 AM | marketbeat.comFORA Capital LLC Makes New $1.12 Million Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 12 at 5:43 AM | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by Fred Alger Management LLCMay 12 at 5:43 AM | marketbeat.comHsbc Holdings PLC Sells 9,437 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)May 12 at 3:44 AM | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Receives Consensus Rating of "Buy" from BrokeragesMay 12 at 2:29 AM | americanbankingnews.com3 Monster Stocks in the MakingMay 11 at 11:15 AM | fool.comFrontier Capital Management Co. LLC Purchases 16,321 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)May 11 at 7:17 AM | marketbeat.comComerica Bank Reduces Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 11 at 4:42 AM | marketbeat.comDAFNA Capital Management LLC Lowers Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 10 at 7:30 AM | marketbeat.comBoone Capital Management LLC Boosts Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 8, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Position Lifted by Braidwell LPMay 8, 2025 | marketbeat.comAptus Capital Advisors LLC Purchases 10,564 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)May 8, 2025 | marketbeat.comCantor Fitzgerald L. P. Takes $380,000 Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 7, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by Bamco Inc. NYMay 7, 2025 | marketbeat.comAQR Capital Management LLC Boosts Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 6, 2025 | marketbeat.comWhy Viking Therapeutics Stock Surged Nearly 20% Higher in AprilMay 6, 2025 | fool.comApis Capital Advisors LLC Has $3.86 Million Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 5, 2025 | marketbeat.com5AM Venture Management LLC Has $7.63 Million Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 4, 2025 | marketbeat.com683 Capital Management LLC Lowers Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 4, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Acquired by MML Investors Services LLCMay 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Viking Therapeutics Stock Pops But Struggles to Hold GainsBy Chris Markoch | April 16, 2025View Viking Therapeutics Stock Pops But Struggles to Hold GainsViking Therapeutics Stock May Struggle After As-Expected ReportBy Chris Markoch | April 25, 2025View Viking Therapeutics Stock May Struggle After As-Expected Report3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.By Leo Miller | April 28, 2025View 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?By Leo Miller | May 6, 2025View Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?MCRB, CBAY, PHAR, and VKTX Company DescriptionsCymaBay Therapeutics NASDAQ:CBAYCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.Seres Therapeutics NASDAQ:MCRB$7.88 +0.83 (+11.77%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$7.55 -0.33 (-4.18%) As of 04:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Pharming Group NASDAQ:PHAR$9.80 -0.23 (-2.24%) Closing price 05/12/2025 03:58 PM EasternExtended Trading$9.81 +0.01 (+0.05%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Viking Therapeutics NASDAQ:VKTX$28.30 +0.75 (+2.72%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$28.40 +0.10 (+0.35%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
